Total Liabilities for IDEXX Laboratories (IDXX)
According to IDEXX Laboratories's latest reported financial statements, the company's latest reported total liabilities is $1.75B USD. Total liabilities sum everything the company owes at the end of each reporting period — accounts payable, accrued expenses, debt, lease obligations, and other claims — as filed on the balance sheet. Compare with total assets and net assets for solvency context.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
Currently viewingTotal LiabilitiesSwitch metric
Latest period
$1.75B
YoY change
+2.8%
5Y CAGR
+1.0%
Peak year (2022)
$2.14B
Latest annual
$1.75B
Total Liabilities history chart for IDEXX Laboratories (IDXX) from 1991 to 2025
Total Liabilities history table for IDEXX Laboratories (IDXX) from 1991 to 2025
| Fiscal year | Period ended | Reported | Total Liabilities | YoY |
|---|---|---|---|---|
| 2025 | $1.75B | +2.8% | ||
| 2024 | $1.70B | -4.4% | ||
| 2023 | $1.78B | -17.0% | ||
| 2022 | $2.14B | +22.4% | ||
| 2021 | $1.75B | +5.1% | ||
| 2020 | $1.66B | +0.4% | ||
| 2019 | $1.65B | +7.0% | ||
| 2018 | $1.55B | -12.5% | ||
| 2017 | $1.77B | +7.8% | ||
| 2016 | $1.64B | +5.1% | ||
| 2015 | $1.56B | +23.1% | ||
| 2014 | $1.27B | +77.8% | ||
| 2013 | $712.30M | +52.4% | ||
| 2012 | $467.35M | -4.9% | ||
| 2011 | $491.22M | +52.1% | ||
| 2010 | $322.86M | +9.8% | ||
| 2009 | $293.95M | -10.2% | ||
| 2008 | $327.24M | +24.0% | ||
| 2007 | $263.86M | +76.3% | ||
| 2006 | $149.70M | +23.3% | ||
| 2005 | $121.37M | +4.1% | ||
| 2004 | $116.58M | +7.4% | ||
| 2003 | $108.58M | +43.5% | ||
| 2002 | $75.68M | +6.0% | ||
| 2001 | $71.38M | -3.6% | ||
| 2000 | $74.05M | -2.4% | ||
| 1999 | $75.90M | -8.2% | ||
| 1998 | $82.70M | +11.3% | ||
| 1997 | $74.30M | +45.1% | ||
| 1996 | $51.20M | +53.3% | ||
| 1995 | $33.40M | +52.5% | ||
| 1994 | $21.90M | +52.1% | ||
| 1993 | $14.40M | +54.8% | ||
| 1992 | $9.30M | +40.9% | ||
| 1991 | $6.60M | — |
Total Liabilities values are taken from IDEXX Laboratories's reported balance sheets (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
2025's annual total liabilities for IDEXX Laboratories (IDXX) came in at $1.75B – edged up 2.8% year-over-year.
Across 2020–2025 (5 years), IDEXX Laboratories total liabilities produced a CAGR of +1.0% – with the latest reading among the more recent periods of the dataset.
$2.14B stands as the all-time-high annual total liabilities, posted in 2022, against a low of $6.60M during 1991.
Among 8 Healthcare peers, IDEXX Laboratories (IDXX) ranks 9th; the peer median for total liabilities is $101.80B.
IDEXX Laboratories Total Liabilities by Year
IDEXX Laboratories Total Liabilities 2025: $1.75B
IDEXX Laboratories total liabilities in 2025 was $1.75B, edged up 2.8% from 2024.
IDEXX Laboratories Total Liabilities 2024: $1.70B
IDEXX Laboratories total liabilities in 2024 was $1.70B, edged down 4.4% below 2023.
IDEXX Laboratories Total Liabilities 2023: $1.78B
IDEXX Laboratories total liabilities in 2023 was $1.78B, declined 17.0% below 2022.
IDEXX Laboratories Total Liabilities 2022: $2.14B
IDEXX Laboratories total liabilities in 2022 was $2.14B, grew 22.4% from 2021. This figure represents the highest annual value in the available history.
IDEXX Laboratories Total Liabilities 2021: $1.75B
IDEXX Laboratories total liabilities in 2021 was $1.75B.
See more financial history for IDEXX Laboratories (IDXX).
Sector peers — Total Liabilities
Companies in the same sector as IDEXX Laboratories, ranked by their latest total liabilities.
| Company | Total Liabilities | Sector |
|---|---|---|
| Novo Nordisk A/S (NVO) | $348.86B | Healthcare |
| UnitedHealth Group Incorporated (UNH) | $207.88B | Healthcare |
| AbbVie Inc. (ABBV) | $137.19B | Healthcare |
| Johnson & Johnson (JNJ) | $117.67B | Healthcare |
| Eli Lilly and Company (LLY) | $85.94B | Healthcare |
| Merck & Co., Inc. (MRK) | $84.20B | Healthcare |
| Amgen Inc. (AMGN) | $81.93B | Healthcare |
| AstraZeneca PLC (AZN) | $65.36B | Healthcare |
Frequently asked questions
What is IDEXX Laboratories's total liabilities?
- Latest reported total liabilities for IDEXX Laboratories (IDXX) is $1.75B (period ending December 31, 2025).
How has IDEXX Laboratories total liabilities changed year-over-year?
- IDEXX Laboratories (IDXX) total liabilities changed +2.8% year-over-year on the latest annual filing.
What is the long-term growth rate of IDEXX Laboratories total liabilities?
- IDEXX Laboratories (IDXX) total liabilities compound annual growth rate is +1.0% over the most recent 5 years available.
When did IDEXX Laboratories total liabilities hit its highest annual value?
- IDEXX Laboratories total liabilities reached its highest annual value of $2.14B in 2022.
What was IDEXX Laboratories total liabilities in 2024?
- IDEXX Laboratories (IDXX) total liabilities in 2024 was $1.70B.
What was IDEXX Laboratories total liabilities in 2025?
- IDEXX Laboratories (IDXX) total liabilities in 2025 was $1.75B.
Metrics overview
Pick a metric for charts, filings, and peers — each row shows the latest TTM or annual value with year-over-year change.
Explore more
IDXX Overview
Company profile, financial tools, and key metrics
IDXX Revenue Counter
Earns $136.47 every second. See per minute, hour, and day.
IDXX Earnings Counter
Earns $33.60 per second net profit. See per minute, hour, and day.
IDXX Economic Scale
Exceeds Aruba's GDP. Compare with world economies.
IDXX What If Invested
What if you had invested $1,000? See historical returns from any date.
IDXX How It Makes Money
Discover visual breakdown of $4.30B in revenue — where it comes from and where it goes.
IDXX Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
IDXX Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
IDXX Daily Price Character
Explosive · 50.9% historical win rate (green days). Streaks & record days.
IDXX Buybacks
2.25% TTM buyback yield. Shareholder yield & SBC comparison.
IDXX Stock Split History
4 splits on record. Dates, ratios, and cumulative multiple.